about
Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancerTreatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsEpidemic of Klebsiella pneumoniae ST11 clone coproducing KPC-2 and 16S rRNA methylase RmtB in a Chinese University HospitalStable susceptibility to aminoglycosides in an age of low level, institutional use.Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management.Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shockGentamicin pharmacokinetics and pharmacodynamics during short-daily hemodialysis.Therapeutic drug monitoring of antimicrobials.Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearanceOptimizing the initial amikacin dosage in adults.How aminoglycosides are used in critically ill patients in a teaching hospital in North of IranA survey on infection management practices in Italian ICUsPharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation.Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis.Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies.Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.Trends in aminoglycoside use and gentamicin-resistant gram-negative clinical isolates in US academic medical centers: implications for antimicrobial stewardship.The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role?Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.
P2860
Q26825326-3801A466-553D-4DFC-A31F-127739C8DE93Q28082546-2E2ECDB5-E53B-4635-98BF-F09D033A07C0Q31109577-5441FA1C-84B7-42FE-A6F2-15916B3A0B2CQ33939064-3AC70C71-07C2-43AA-ACE6-348AA8CAFB1EQ34437229-818F83E2-1A6E-423F-80BA-4AFF5B1E41D3Q34597640-EC334C3C-F0B1-4C3F-8AA9-099D341138AFQ35001792-F2A6E3BD-2AB2-4CDE-85EF-ADDCD09C8D2DQ35640430-4EE51F7C-E0D5-4FFF-B5AE-98A6CB4555D9Q36089167-40F2CBCB-EAB3-4B49-A631-606C96BDB546Q36158283-2BC6A521-A610-46F3-89C1-9F1418CABAE4Q36290910-738005A6-106B-42BC-99D2-C1AFFBE26C33Q36902763-FD0575E6-FBC6-4A0F-A206-6BE71018AD19Q37263821-B958427B-A773-4CCF-87D5-585FAA2B70A4Q38090988-EF6A23E9-79F9-4D88-BBD8-222556F6E478Q38672016-6F2E2F7F-5FC4-4557-A529-52EDF750DBAEQ39431158-84E9D13B-5ABD-4CE6-90F9-74201A223F61Q40175242-1B7E1C6D-AD97-41D9-A383-ADA9ED136CD2Q40474926-CECB495F-9D46-4907-AB7A-830758CC5B89Q44975350-4362C891-1D1F-4DBD-8EA1-35F1162A74A4Q47939381-775FCB1B-BB5A-4EC6-8D95-5B23850E7F3BQ52695014-4203D98A-3052-43AB-8BAD-0476F8E008F2
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Optimization of aminoglycoside therapy.
@ast
Optimization of aminoglycoside therapy.
@en
type
label
Optimization of aminoglycoside therapy.
@ast
Optimization of aminoglycoside therapy.
@en
prefLabel
Optimization of aminoglycoside therapy.
@ast
Optimization of aminoglycoside therapy.
@en
P2860
P356
P1476
Optimization of aminoglycoside therapy.
@en
P2093
Arnold Louie
G L Drusano
P2860
P304
P356
10.1128/AAC.01314-10
P407
P577
2011-03-14T00:00:00Z